Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Advanced glycation end products as environmental risk factors for the development of type 1 diabetes.

Yap FY, Kantharidis P, Coughlan MT, Slattery R, Forbes JM.

Curr Drug Targets. 2012 Apr;13(4):526-40. Review.

PMID:
22250649
2.

Cardiovascular disease: what's all the AGE/RAGE about?

Barlovic DP, Thomas MC, Jandeleit-Dahm K.

Cardiovasc Hematol Disord Drug Targets. 2010 Mar;10(1):7-15. Review.

PMID:
20041839
3.
4.

The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus.

Hori O, Yan SD, Ogawa S, Kuwabara K, Matsumoto M, Stern D, Schmidt AM.

Nephrol Dial Transplant. 1996;11 Suppl 5:13-6. Review.

PMID:
9044300
5.

Understanding RAGE, the receptor for advanced glycation end products.

Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, Stern DM, Nawroth PP.

J Mol Med (Berl). 2005 Nov;83(11):876-86. Epub 2005 Aug 24. Review.

PMID:
16133426
6.

The AGE/RAGE axis in diabetes-accelerated atherosclerosis.

Jandeleit-Dahm K, Watson A, Soro-Paavonen A.

Clin Exp Pharmacol Physiol. 2008 Mar;35(3):329-34. doi: 10.1111/j.1440-1681.2007.04875.x. Review.

PMID:
18290873
7.

AGE-RAGE and AGE Cross-link interaction: important players in the pathogenesis of diabetic kidney disease.

Jensen LJ, Ƙstergaard J, Flyvbjerg A.

Horm Metab Res. 2005 Apr;37 Suppl 1:26-34. Review.

PMID:
15918107
8.

Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy.

Yamagishi S, Nakamura K, Matsui T.

Curr Drug Discov Technol. 2006 Mar;3(1):83-8. Review.

PMID:
16712466
9.

Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.

Yamagishi S.

Exp Gerontol. 2011 Apr;46(4):217-24. doi: 10.1016/j.exger.2010.11.007. Epub 2010 Nov 25. Review.

PMID:
21111800
10.

Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.

Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S.

Expert Opin Investig Drugs. 2008 Jul;17(7):983-96. doi: 10.1517/13543784.17.7.983 . Review.

PMID:
18549336
11.

Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.

Yamagishi S.

Ther Apher Dial. 2009 Dec;13(6):534-9. doi: 10.1111/j.1744-9987.2009.00775.x. Review.

PMID:
19954478
12.

Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.

Geroldi D, Falcone C, Emanuele E.

Curr Med Chem. 2006;13(17):1971-8. Review.

PMID:
16842191
13.

Advanced glycation end products and insulin resistance.

Unoki H, Yamagishi S.

Curr Pharm Des. 2008;14(10):987-9. Review.

PMID:
18473850
14.

Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes.

Stern DM, Yan SD, Yan SF, Schmidt AM.

Ageing Res Rev. 2002 Feb;1(1):1-15. Review.

PMID:
12039445
15.
16.
17.

Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.

Yan SF, Ramasamy R, Schmidt AM.

Nat Clin Pract Endocrinol Metab. 2008 May;4(5):285-93. doi: 10.1038/ncpendmet0786. Epub 2008 Mar 11. Review.

PMID:
18332897
18.

The AGE-RAGE system and diabetic nephropathy.

Sakurai S, Yonekura H, Yamamoto Y, Watanabe T, Tanaka N, Li H, Rahman AK, Myint KM, Kim CH, Yamamoto H.

J Am Soc Nephrol. 2003 Aug;14(8 Suppl 3):S259-63. Review.

19.

The role of AGEs in cardiovascular disease.

Jandeleit-Dahm K, Cooper ME.

Curr Pharm Des. 2008;14(10):979-86. Review.

PMID:
18473849
20.

Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease.

Takeuchi M, Yamagishi S.

Curr Pharm Des. 2008;14(10):973-8. Review.

PMID:
18473848

Supplemental Content

Support Center